WS #11553

From 500 msgs · 29 key-dev

Vertex acquires Crinetics for $85/share cash (~$10B), adding FDA-approved PALSONIFY and late-stage CAH therapy; accretive to non-GAAP op income by 2029.

Vertex-Crinetics $10B Acquisition

Vertex acquires Crinetics for $85/share cash (~$10B), adding FDA-approved PALSONIFY and late-stage CAH therapy; accretive to non-GAAP op income by 2029.

Full world state #11553 →